Skip to content

Study · Randomized controlled trial · 2023

3 results

The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.

Bjorner JB, Larsen S, Lübker C, Holst-Hansen T

Diabetes, obesity & metabolism8 May 2023Cited by 4 (Europe PMC)

PMID37055712 (opens in a new tab)DOI10.1111/dom.15090 (opens in a new tab)PepBankPUB-37055712
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity in the STEP 1-4 trials, semaglutide 2.4 mg was associated with minor improvements in health utility scores from baseline at week 68, while placebo scores typically decreased.

    In plain wordsIn adults with obesity, semaglutide 2.4 mg was linked to small gains in health utility scores, while scores usually fell with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseHealth utility score change from baseline at week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 68, semaglutide 2.4 mg was associated with minor health utility score improvements from baseline (all trials), while scores for placebo typically decreased.
    1 context sentence
    Summary · context
    The STEP 1-4 phase 3a, 68-week, double-blind randomized controlled trials assessed the efficacy and safety of semaglutide 2.4 mg versus placebo in individuals with a body mass index (BMI) of 30 kg/m2 or higher or a BMI of 27 kg/m2 or higher and at least one comorbidity (STEP 1,…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, the SF-6Dv2 utility difference at week 68 for semaglutide 2.4 mg versus placebo was significant in STEP 1 and 4 but not in STEP 2 or 3.

    In plain wordsIn adults with obesity, semaglutide 2.4 mg improved one health utility score more than placebo in two of four trials.

    Peptide
    Semaglutide
    Outcome
    MixedSF-6Dv2 utility treatment difference at week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    SF-6Dv2 treatment differences by week 68 for semaglutide 2.4 mg versus placebo were significant in STEP 1 and 4 (P ≤ .001), but not STEP 2 or 3.
    1 context sentence
    Summary · context
    The STEP 1-4 phase 3a, 68-week, double-blind randomized controlled trials assessed the efficacy and safety of semaglutide 2.4 mg versus placebo in individuals with a body mass index (BMI) of 30 kg/m2 or higher or a BMI of 27 kg/m2 or higher and at least one comorbidity (STEP 1,…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, the EQ-5D-3L utility difference at week 68 for semaglutide 2.4 mg versus placebo was significant in STEP 1, 2 and 4 but not in STEP 3.

    In plain wordsIn adults with obesity, semaglutide 2.4 mg improved a second health utility score more than placebo in three of four trials.

    Peptide
    Semaglutide
    Outcome
    MixedEQ-5D-3L utility treatment difference at week 68
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    EQ-5D-3L treatment differences by week 68 for semaglutide 2.4 mg versus placebo were significant in STEP 1, 2 and 4 (P < .001 for all), but not STEP 3.
    1 context sentence
    Summary · context
    The STEP 1-4 phase 3a, 68-week, double-blind randomized controlled trials assessed the efficacy and safety of semaglutide 2.4 mg versus placebo in individuals with a body mass index (BMI) of 30 kg/m2 or higher or a BMI of 27 kg/m2 or higher and at least one comorbidity (STEP 1,…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.